These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 28736235)

  • 1. HLA-A*26 Is Correlated With Response to Nivolumab in Japanese Melanoma Patients.
    Ishida Y; Otsuka A; Tanaka H; Levesque MP; Dummer R; Kabashima K
    J Invest Dermatol; 2017 Nov; 137(11):2443-2444. PubMed ID: 28736235
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy of nivolumab monotherapy against acral lentiginous melanoma and mucosal melanoma in Asian patients.
    Maeda T; Yoshino K; Nagai K; Oaku S; Kato M; Hiura A; Hata H
    Br J Dermatol; 2019 May; 180(5):1230-1231. PubMed ID: 30447078
    [No Abstract]   [Full Text] [Related]  

  • 3. Retrospective study of advanced melanoma patients treated with ipilimumab after nivolumab: Analysis of 60 Japanese patients.
    Fujisawa Y; Yoshino K; Otsuka A; Funakoshi T; Uchi H; Fujimura T; Matsushita S; Hata H; Okuhira H; Tanaka R; Nagai K; Ishida Y; Nakamura Y; Furudate S; Yamamura K; Imafuku K; Yamamoto Y
    J Dermatol Sci; 2018 Jan; 89(1):60-66. PubMed ID: 29079332
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predicting marker for early progression in unresectable melanoma treated with nivolumab.
    Kondo T; Nomura M; Otsuka A; Nonomura Y; Kaku Y; Matsumoto S; Muto M
    Int J Clin Oncol; 2019 Mar; 24(3):323-327. PubMed ID: 30168088
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term follow up of nivolumab in previously untreated Japanese patients with advanced or recurrent malignant melanoma.
    Yamazaki N; Kiyohara Y; Uhara H; Uehara J; Fujisawa Y; Takenouchi T; Otsuka M; Uchi H; Ihn H; Hatsumichi M; Minami H
    Cancer Sci; 2019 Jun; 110(6):1995-2003. PubMed ID: 30959557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dermoscopic changes in malignant melanoma after successful treatment with nivolumab: A case report.
    Yamamura K; Otsuka A; Kaku Y; Seidel JA; Nomura M; Nagai H; Matsumoto S; Kabashima K
    J Dermatol; 2017 May; 44(5):547-548. PubMed ID: 27461159
    [No Abstract]   [Full Text] [Related]  

  • 7. Treatment of a patient with HIV and metastatic melanoma with consequitive ipilimumab and nivolumab.
    Tomsitz D; Hein R; Biedermann T; Kohlmeyer J
    J Eur Acad Dermatol Venereol; 2018 Jan; 32(1):e26-e28. PubMed ID: 28662283
    [No Abstract]   [Full Text] [Related]  

  • 8. Baseline neutrophil to lymphocyte ratio combined with serum lactate dehydrogenase level associated with outcome of nivolumab immunotherapy in a Japanese advanced melanoma population.
    Fujisawa Y; Yoshino K; Otsuka A; Funakoshi T; Fujimura T; Yamamoto Y; Hata H; Tanaka R; Yamaguchi K; Nonomura Y; Hirai I; Furudate S; Okuhira H; Imafuku K; Aoki M; Matsushita S
    Br J Dermatol; 2018 Jul; 179(1):213-215. PubMed ID: 29405254
    [No Abstract]   [Full Text] [Related]  

  • 9. Using immune checkpoint inhibitors without exacerbation in a melanoma patient with pemphigus foliaceus.
    Maeda T; Yanagi T; Imafuku K; Kitamura S; Hata H; Izumi K; Ujiie H; Iwata H; Shimizu H
    Int J Dermatol; 2017 Dec; 56(12):1477-1479. PubMed ID: 28762466
    [No Abstract]   [Full Text] [Related]  

  • 10. Use of immune checkpoint inhibitors prolonged overall survival in a Japanese population of advanced malignant melanoma patients: Retrospective single institutional study.
    Nakamura Y; Fujisawa Y; Tanaka R; Maruyama H; Ishitsuka Y; Okiyama N; Watanabe R; Fujimoto M
    J Dermatol; 2018 Nov; 45(11):1337-1339. PubMed ID: 30204266
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Unresectable Non-metastatic Primary Melanoma: Complete Remission Following Treatment with Anti-Programmed-cell-death-receptor 1.
    Lheure C; Hoffmann C; Kramkimel N; Plée J; Franck N; Vanhaecke C; Goldman-Lévy G; Bataillon G; Damotte D; Dupin N; Aractingi S; Grange F; Guégan S
    Acta Derm Venereol; 2019 Jan; 99(1):107-108. PubMed ID: 30176045
    [No Abstract]   [Full Text] [Related]  

  • 12. Are checkpoint inhibitors a valuable option for metastatic or unresectable vulvar and vaginal melanomas?
    Quéreux G; Wylomanski S; Bouquin R; Saint-Jean M; Peuvrel L; Knol AC; Hanf M; Dréno B
    J Eur Acad Dermatol Venereol; 2018 Jan; 32(1):e39-e40. PubMed ID: 28750150
    [No Abstract]   [Full Text] [Related]  

  • 13. Efficacy and safety of nivolumab in metastatic melanoma: real-world practice.
    Bocquet-Tremoureux S; Scharbarg E; Nguyen JM; Varey E; Quereux G; Saint-Jean M; Peuvrel L; Khammari A; Dreno B
    Eur J Dermatol; 2019 Jun; 29(3):315-321. PubMed ID: 31389790
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor mutational burden and response to programmed cell death protein 1 inhibitors in a case series of patients with metastatic desmoplastic melanoma.
    Boussemart L; Johnson A; Schrock AB; Pal SK; Frampton GM; Fabrizio D; Chalmers Z; Lotem M; Gibney G; Russell J; Chmielowski B; Ross JS; Stephens PJ; Miller VA; Ali SM
    J Am Acad Dermatol; 2019 Jun; 80(6):1780-1782. PubMed ID: 30576761
    [No Abstract]   [Full Text] [Related]  

  • 15. MicroRNAs that predict the effectiveness of anti-PD-1 therapies in patients with advanced melanoma.
    Nakahara S; Fukushima S; Okada E; Morinaga J; Kubo Y; Tokuzumi A; Matsumoto S; Tsuruta-Kadohisa M; Kimura T; Kuriyama H; Miyashita A; Kajihara I; Jinnin M; Ihn H
    J Dermatol Sci; 2020 Jan; 97(1):77-79. PubMed ID: 31843231
    [No Abstract]   [Full Text] [Related]  

  • 16. Two cases of dabrafenib and trametinib therapy-failed advanced melanoma successfully controlled by nivolumab monotherapy.
    Sato Y; Fujimura T; Kambayashi Y; Tanita K; Tono H; Hashimoto A; Aiba S
    J Dermatol; 2018 Sep; 45(9):1105-1108. PubMed ID: 29923635
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of Immune Reaction in Benign Melanocytic Nevi Without Halo During Nivolumab Therapy in a Patient With Melanoma.
    Nakamura Y; Fujino T; Kagamu H; Matsuya T; Teramoto Y; Asami Y; Yamamoto A
    JAMA Dermatol; 2017 Aug; 153(8):832-834. PubMed ID: 28492864
    [No Abstract]   [Full Text] [Related]  

  • 18. Nivolumab for adjuvant treatment of desmoplastic malignant melanoma: A case report.
    Shibata T; Iwashita N; Takama H; Yanagishita T; Takeo T; Oshima Y; Watanabe D; Tsuzuki T
    J Dermatol; 2020 Jan; 47(1):e6-e7. PubMed ID: 31701575
    [No Abstract]   [Full Text] [Related]  

  • 19. Development of endocrine immune-related adverse events and improved survival in advanced melanoma patients treated with nivolumab monotherapy.
    Maeda T; Yoshino K; Nagai K; Oaku S; Kato M; Hiura A; Hata H
    Eur J Cancer; 2019 Jul; 115():13-16. PubMed ID: 31082687
    [No Abstract]   [Full Text] [Related]  

  • 20. Exposure-Response Analysis of Nivolumab in Patients With Previously Treated or Untreated Advanced Melanoma.
    Bajaj G; Gupta M; Feng Y; Statkevich P; Roy A
    J Clin Pharmacol; 2017 Dec; 57(12):1527-1533. PubMed ID: 28800166
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.